WO2022188867A1 - Procédé d'amélioration de l'innocuité d'un médicament contenant un fragment fc d'immunoglobuline - Google Patents

Procédé d'amélioration de l'innocuité d'un médicament contenant un fragment fc d'immunoglobuline Download PDF

Info

Publication number
WO2022188867A1
WO2022188867A1 PCT/CN2022/080392 CN2022080392W WO2022188867A1 WO 2022188867 A1 WO2022188867 A1 WO 2022188867A1 CN 2022080392 W CN2022080392 W CN 2022080392W WO 2022188867 A1 WO2022188867 A1 WO 2022188867A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
variable region
acid sequence
immunoglobulin
Prior art date
Application number
PCT/CN2022/080392
Other languages
English (en)
Chinese (zh)
Inventor
张鹏
李百勇
夏瑜
王忠民
Original Assignee
中山康方生物医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中山康方生物医药有限公司 filed Critical 中山康方生物医药有限公司
Publication of WO2022188867A1 publication Critical patent/WO2022188867A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the present invention belongs to the field of tumor therapy and molecular immunology, and relates to a method for optimizing the safety and/or effectiveness of a drug (such as an antibody or Fc fusion protein) containing an immunoglobulin Fc fragment.
  • a drug such as an antibody or Fc fusion protein
  • the present invention relates to a method of reducing or blocking the levels of IL-8 and/or IL-6 secreted by immune cells mediated by drugs containing immunoglobulin Fc fragments (eg, antibodies or Fc fusion proteins).
  • Fc receptors are immunoglobulin family proteins that are expressed on the surface of specific immune cells or somatic cells and are used to recognize the Fc region of antibodies to mediate immune responses. After the Fab region of the antibody recognizes the antigen, the Fc region of the antibody binds to Fc receptors on immune cells (such as killer cells) to activate effector cells.
  • Fc receptors are mainly divided into three types: Fc ⁇ R, Fc ⁇ R and Fc ⁇ R.
  • Fc ⁇ R can be further divided into Fc ⁇ RI (also known as CD64), Fc ⁇ RII (also known as CD32), Fc ⁇ RIII (also known as CD16) and FcRn (also known as Neonatal Fc receptor) four subtypes.
  • Fc ⁇ RI, Fc ⁇ RII and Fc ⁇ RIII are closely related to ADCC effect.
  • Fc ⁇ RIII is the most important molecule mediating ADCC. It has two isoforms, Fc ⁇ RIIIa and Fc ⁇ RIIIb, which are highly homologous in different cell types.
  • Fc ⁇ RIIIa There is a high-affinity Fc ⁇ RIIIa subtype caused by mononuclear stem polymorphism (SNP) in the Fc ⁇ RIIIa population.
  • SNP mononuclear stem polymorphism
  • Fc ⁇ RI has a high affinity for the Fc region of IgG and participates in the ADCC process;
  • Fc ⁇ RII has three subtypes: Fc ⁇ RIIa, Fc ⁇ RIIb and Fc ⁇ RIIc (also known as CD32a, CD32b, CD32c), of which Fc ⁇ RIIa has ADCC activity;
  • Fc ⁇ RIIa exists in the population The two isoforms due to single nucleotide mutations are called Fc ⁇ RIIa_H131 and Fc ⁇ RIIa_R131 (Hogarth PM, Pietersz GA. 2012, Nature Review Drug Discovery, 11(4):311-331).
  • the IgG family consists of four members, IgG1, IgG2, IgG3 and IgG4, which have amino acid differences in the fragment crystallizable (Fc) region of their heavy chain constant regions, resulting in their different affinities with Fc ⁇ Rs.
  • IgG1 is the most subtype in the human body and the most used subtype in monoclonal antibody drugs. IgG1 can bind to various Fc ⁇ Rs.
  • IgG2 has the weakest affinity for Fc ⁇ Rs, but IgG2 is still able to bind to Fc ⁇ RIIa.
  • IgG3 has the strongest binding ability to Fc ⁇ Rs.
  • IgG4 molecules bind weakly to Fc ⁇ Rs other than Fc ⁇ RI.
  • the IgG4 antibody subtype is unstable and prone to breakage in the hinge region, which leads to Fab-arm exchange, forming half-molecular and bispecific functional monovalent antibodies (Aalberse R.C.et al.Clin.Exp.Allergy.2009;39(4):469 -77.);
  • the introduction of S228P mutation into the hinge region of IgG4 antibody heavy chain can stabilize IgG4 molecule and prevent the formation of half-molecule (Shirley J Peters et al. J Biol Chem. 2012 13; 287(29): 24525-33.).
  • ADCR antibody-dependent cytokine release
  • the Fab segment of the antibody binds to the antigenic epitope of the tumor cell, and the Fc segment cross-binding with the Fc receptor (Fc Receptor, FcR) on the effector cell surface, through crosslinking Activation of effector cells, resulting in a large amount of cytokines secreted by activated effector cells, such as IL (interleukin)-1, IL-6, IL-8, IL-10, MCP (monocyte chemotactic protein)-1, etc. , of which IL-6 is the main inflammatory mediator.
  • IL interleukin
  • IL-8 interleukin-8
  • IL-10 MCP (monocyte chemotactic protein)-1, etc.
  • MCP monocyte chemotactic protein
  • Interleukin-8 (interleutin-8, IL-8) is a chemotactic cytokine (Chemotactic cytokines), belonging to the CXC- ⁇ subfamily (also known as CXCL-8). In normal humans, it is mainly secreted by monocytes, immune cells, epithelial cells, etc., and is involved in inflammation and immune defense responses in the body; its receptor (CXCR) is a dimer sugar composed of two subunits of 59 and 67 kDa. The protein, belonging to the G protein-coupled receptor superfamily, has two subtypes, CXCR1 and CXCR2. IL-8 plays an important role in the proliferation of normal cells and tumor cells, especially in promoting the occurrence and development of tumors.
  • IL-8 can promote tumorigenesis; tumor cells themselves can also secrete IL-8 to promote tumor growth and metastasis (Lo MC et al. Cancer letters, 2013, 335(1):81-92.). Therefore, IL-8 has become an indispensable and important inflammatory factor in the tumor microenvironment.
  • IL-8 As a pro-inflammatory factor, IL-8 is closely related to the occurrence and development of tumors. In the process of methylarsonate-induced malignant transformation of non-renal cancer cells, the expression of IL-8 gene is increased, and IL-8 gene silencing can significantly inhibit the growth of transplanted tumors in mice. In addition, the level of IL-8 decreases. It can inhibit the expression of matrix metalloproteinase-9 (Matrix metalloproteinase-9), cyclin D1 (Cyclin D1), pro-apoptotic protein Bcl-2, and vascular endothelial growth factor (VEGF) related to tumor growth and metastasis (Escudero -Lourdes C et al.
  • matrix metalloproteinase-9 matrix metalloproteinase-9
  • Cyclin D1 Cyclin D1
  • VEGF vascular endothelial growth factor
  • IL-8 induced the malignant transformation and increased invasiveness of non-neoplastic bladder cell line (233JP), while the probability of malignant transformation of 233JP cells was significantly reduced in IL-8 knockout mice (Inoue K et al. al. Cancer Res, 2000, 60(8):2290-2299.).
  • IL-8 can promote the occurrence of castration-resistant prostate cancer (CRPC) in patients (Chen K et al. Cancer research, 2015, 75(10): 1992-2004.), and is closely related to tumor therapy (Araki S et al.
  • IL-6 is rapidly produced mainly by macrophages in response to pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) and protects damaged tissues by removing infectious agents, inducing acute phase and immune responses effect.
  • PAMPs pathogen-associated molecular patterns
  • DAMPs damage-associated molecular patterns
  • IL-6 is also responsive to ligands including Toll-like receptor (TLR) and pro-inflammatory cytokines such as IL-1 and TNF-[alpha].
  • TLR Toll-like receptor
  • cytokines such as IL-1 and TNF-[alpha].
  • IL-6 is produced by stimulation of TLRs on monocytes and macrophages, each of which recognizes the corresponding bacterial, viral or fungal components such as lipopolysaccharide, CpG DNA, double- or single-stranded RNA And peptidoglycan, PAMP.
  • IL-6 can also be produced in non-infectious inflammations such as burns and wounds, and its levels depend on the severity of the disease.
  • Damaged or necrotic cells and damaged or degraded extracellular matrix are released through DAMP mode such as mitochondrial DNA, high mobility group box chromosomal protein 1 (HMGB1), heat shock protein and S100 molecules, etc., and then stimulate the corresponding TLR production including IL-6 of proinflammatory cytokines.
  • DAMP mode such as mitochondrial DNA, high mobility group box chromosomal protein 1 (HMGB1), heat shock protein and S100 molecules, etc.
  • IL-6 plays an important role in the resistance and repair of infection and tissue damage, high levels of IL-6 can activate coagulation pathways and vascular endothelial cells, thereby inhibiting myocardial function, and even causing "cytokine storm", resulting in severe acute systemic inflammatory response. Cytokine storm is a fatal complication and adverse reaction in viral infection and tumor immunotherapy.
  • Immune-related adverse reactions are a common and dangerous adverse reaction in immune checkpoint inhibitor (ICI) antitumor therapy (Spain L et al. Cancer Treat Rev. 2016; 44:51-60.).
  • immune checkpoint inhibitors have achieved great success in tumor immunotherapy, but they have also led to a completely new toxicity spectrum due to off-target effects.
  • Serious immune-related adverse events irAEs
  • major organs including heart, lung, and brain, can be life-threatening (Bergqvist V, et al. Cancer Immunol Immunother.
  • ICI may induce off-target effects through four mechanisms, including direct binding to immune checkpoint molecules expressed on the surface of normal cells, activation of complement hypersensitivity; the existence of homologous antigens/epitopes in normal tissues and tumor cells; production of autoantibodies; Increased levels of pro-inflammatory cytokines, such as IL-6, etc. (Martins F et al., The Lancet Oncology, 20(1), e54–e64.).
  • Fc fusion protein drugs such as IL-2-Fc fusion protein
  • IL-2-Fc fusion protein have been proven to be used to treat tumors, but due to their inherent toxicity, such as IL-2-Fc fusion protein can cause lethal capillary Vascular leak disease, and induce proliferation of immunosuppressive Treg cells, affecting its anti-tumor activity, if its Fc fragment can further induce immune cells to secrete IL-8 and/or IL-6, it will significantly affect its anti-tumor effectiveness and safety. These all limit its clinical application.
  • Fc fusion protein drugs especially antibody drugs targeting immune checkpoints and Fc fusion protein drugs with cytokines, chemokines and their ligands as the mechanism of action, inhibit Its effect of inducing immune cells to secrete IL-8 and/or IL-6 is of great significance for improving the efficacy and/or safety of the drug.
  • anti-dual immune checkpoint inhibitors anti-PD-1/CTLA4 bispecific antibody, anti-PD-1/CD73 bispecific antibody, anti-PD-1/LAG3 bispecific antibody
  • an Fc fusion protein with immunomodulatory biological activity such as a fusion protein of IL-2 and Fc
  • an Fc fusion protein with immunomodulatory biological activity can effectively reduce or eliminate immune checkpoint therapy antibodies or fusion protein-mediated or Induced unintended activity of immune cells to secrete IL-6 and/or IL-8, thereby increasing the safety and/or efficacy of immune checkpoint inhibitors and fusion protein drugs.
  • One aspect of the present invention pertains to a method for reducing the level of IL-8 and/or IL-6 secreted by immune cells mediated or induced by a drug containing an immunoglobulin Fc fragment, comprising the steps of:
  • the immunoglobulin Fc fragment contains the following mutations:
  • the method wherein the drug containing an immunoglobulin Fc fragment comprises an antibody and/or an Fc fusion protein;
  • the medicine containing the immunoglobulin Fc fragment further comprises one or more pharmaceutically acceptable excipients.
  • the method wherein the drug containing an immunoglobulin Fc fragment is an antibody.
  • the method wherein the drug containing an immunoglobulin Fc fragment is an Fc fusion protein.
  • the method wherein the drug containing an immunoglobulin Fc fragment is an antibody and an Fc fusion protein.
  • the method wherein the medicament containing an immunoglobulin Fc fragment comprises an antibody and/or Fc fusion protein as an active ingredient (API), and one or more pharmaceutically acceptable excipients.
  • API active ingredient
  • the method wherein the immunoglobulin Fc fragment-containing drug is composed of an antibody and/or Fc fusion protein as an active ingredient (API), and one or more pharmaceutically Acceptable excipient composition.
  • API active ingredient
  • the method wherein the immunoglobulin Fc fragment-containing medicament comprises as the sole active ingredient (API) an antibody and/or Fc fusion protein, and one or more pharmaceutical agents acceptable excipients.
  • API active ingredient
  • the method wherein the immunoglobulin Fc fragment-containing drug is composed of an antibody and/or Fc fusion protein as the sole active ingredient (API), and one or more pharmaceutical agents composition of acceptable excipients.
  • API active ingredient
  • the drug containing the immunoglobulin Fc fragment contains one or more pharmaceutically acceptable excipients, it is actually a pharmaceutical composition.
  • Various dosage forms, such as injections, can be prepared according to the skills of those skilled in the art.
  • the method wherein the antibody is an immune checkpoint inhibitor.
  • the method wherein the antibody is a bispecific antibody or a multispecific antibody.
  • the method, wherein the antibody targets :
  • PD-1 and CTLA4 PD-1 and CD73, PD-1 and LAG3, CTLA4 and CD73, CTLA4 and LAG3, or CD73 and LAG3.
  • the method, wherein the bispecific antibody targets PD-1 and CTLA4 comprises:
  • the first protein functional region is an immunoglobulin
  • the second protein functional region is a single-chain antibody
  • the first protein functional region is a single-chain antibody
  • the second protein functional region is an immunoglobulin protein
  • Described immunoglobulin its heavy chain variable region comprises the HCDR1-HCDR3 shown in amino acid sequence respectively as SEQ ID NOs:32-34, and its light chain variable region comprises aminoacid sequence respectively as SEQ ID NOs:35-37
  • LCDR1-LCDR3 as shown in SEQ ID NOs: 41-43;
  • Described immunoglobulin its heavy chain variable region comprises the HCDR1-HCDR3 shown in amino acid sequence respectively as SEQ ID NOs:38-40, and its light chain variable region comprises aminoacid sequence respectively as SEQ ID NOs:41-43 Shown LCDR1-LCDR3; And described single chain antibody, its heavy chain variable region comprises the HCDR1-HCDR3 shown in SEQ ID NOs:32-34 respectively, and its light chain variable region comprises amino acid sequence respectively.
  • LCDR1-LCDR3 as shown in SEQ ID NOs: 35-37;
  • the immunoglobulin is human IgG
  • each single-chain antibody is respectively connected to the C-terminus of the two heavy chains of immunoglobulin.
  • the amino acid sequence of the heavy chain variable region of the immunoglobulin is selected from SEQ ID NO: 2 and SEQ ID NO: 6; and the amino acid sequence of the light chain variable region of the immunoglobulin is selected from SEQ ID NO: 4 , SEQ ID NO:8 and SEQ ID NO:64; and the amino acid sequence of the heavy chain variable region of the single chain antibody is selected from the group consisting of SEQ ID NO:14, SEQ ID NO:18 and SEQ ID NO:30; and The amino acid sequence of the light chain variable region of the single chain antibody is selected from SEQ ID NO: 16, SEQ ID NO: 20 and SEQ ID NO: 31;
  • the amino acid sequence of the heavy chain variable region of the immunoglobulin is selected from SEQ ID NO: 14, SEQ ID NO: 18 and SEQ ID NO: 30; and the amino acid sequence of the light chain variable region of the immunoglobulin is selected from the group consisting of: and, the amino acid sequence of the heavy chain variable region of the single chain antibody is selected from SEQ ID NO: 2 and SEQ ID NO: 6; and The amino acid sequence of the light chain variable region of the single chain antibody is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:8 and SEQ ID NO:64.
  • the method, wherein the bispecific antibody is selected from any one of the following (1)-(18):
  • amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 4; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 16;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 4; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 20;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 4; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 30, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 31;
  • amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 8; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 16;
  • amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 8; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 20;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 8; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 30, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 31;
  • amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 64; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 16;
  • amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 64; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 20;
  • amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 64; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 30, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 31;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 16; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 4;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 16; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 8;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 16; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 64;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 20; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 4;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 20; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 8;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 20; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 64;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 30, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 31; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 4;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 30, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 31; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 8;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 30, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 31; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 64.
  • the method, wherein the bispecific antibody targets CD73 and PD-1 comprises:
  • the first protein functional region is an immunoglobulin
  • the second protein functional region is a single-chain antibody
  • the first protein functional region is a single-chain antibody
  • the second protein functional region is an immunoglobulin protein
  • Described immunoglobulin its heavy chain variable region comprises the HCDR1-HCDR3 shown in amino acid sequence as SEQ ID NOs:44-46 respectively, and its light chain variable region comprises aminoacid sequence respectively as SEQ ID NOs:47-49 Shown LCDR1-LCDR3; And described single chain antibody, its heavy chain variable region comprises the HCDR1-HCDR3 shown in SEQ ID NOs:32-34 respectively, and its light chain variable region comprises amino acid sequence respectively.
  • LCDR1-LCDR3 as shown in SEQ ID NOs: 35-37;
  • Described immunoglobulin its heavy chain variable region comprises the HCDR1-HCDR3 shown in amino acid sequence respectively as SEQ ID NOs:32-34, and its light chain variable region comprises aminoacid sequence respectively as SEQ ID NOs:35-37 Shown LCDR1-LCDR3; And described single chain antibody, its heavy chain variable region comprises the HCDR1-HCDR3 shown in SEQ ID NOs:44-46 respectively, and its light chain variable region comprises amino acid sequence respectively.
  • LCDR1-LCDR3 as shown in SEQ ID NOs: 47-49;
  • the immunoglobulin is human IgG
  • each single-chain antibody is respectively connected to the C-terminus of the two heavy chains of immunoglobulin.
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is selected from SEQ ID NO: 22; and the amino acid sequence of the variable region of the light chain of the immunoglobulin is selected from SEQ ID NO: 26;
  • the amino acid sequence of the heavy chain variable region of the chain antibody is selected from SEQ ID NO: 2 and SEQ ID NO: 6; and the amino acid sequence of the light chain variable region of the single chain antibody is selected from SEQ ID NO: 4, SEQ ID NO: 6; NO:8 and SEQ ID NO:64;
  • the amino acid sequence of the heavy chain variable region of the immunoglobulin is selected from SEQ ID NO: 2 and SEQ ID NO: 6; and the amino acid sequence of the light chain variable region of the immunoglobulin is selected from SEQ ID NO: 4 , SEQ ID NO: 8 and SEQ ID NO: 64; and the amino acid sequence of the heavy chain variable region of the single chain antibody is selected from SEQ ID NO: 22; and the light chain variable region of the single chain antibody
  • the amino acid sequence is selected from SEQ ID NO:26.
  • the method, wherein the bispecific antibody is selected from any one of the following (1)-(6):
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 22, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 26; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 4;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 22, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 26; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 8;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 22, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 26; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 64;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 4; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 22, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 26;
  • amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 8; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 22, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 26;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 64; and, the The amino acid sequence of the variable region of the heavy chain of the single chain antibody is shown in SEQ ID NO: 22, and the amino acid sequence of the variable region of the light chain of the single chain antibody is shown in SEQ ID NO: 26.
  • the method, wherein the bispecific antibody targets LAG3 and PD-1 comprises:
  • the first protein functional region is an immunoglobulin
  • the second protein functional region is a single-chain antibody
  • the first protein functional region is a single-chain antibody
  • the second protein functional region is an immunoglobulin protein
  • Described immunoglobulin its heavy chain variable region comprises the HCDR1-HCDR3 shown in amino acid sequence as SEQ ID NOs:50-52 respectively, and its light chain variable region comprises aminoacid sequence respectively as SEQ ID NOs:53-55 Shown LCDR1-LCDR3; And described single chain antibody, its heavy chain variable region comprises the HCDR1-HCDR3 shown in SEQ ID NOs:32-34 respectively, and its light chain variable region comprises amino acid sequence respectively.
  • LCDR1-LCDR3 as shown in SEQ ID NOs: 35-37;
  • Described immunoglobulin its heavy chain variable region comprises the HCDR1-HCDR3 shown in amino acid sequence respectively as SEQ ID NOs:32-34, and its light chain variable region comprises aminoacid sequence respectively as SEQ ID NOs:35-37 Shown LCDR1-LCDR3; And described single chain antibody, its heavy chain variable region comprises the HCDR1-HCDR3 shown in SEQ ID NOs:50-52 respectively, and its light chain variable region comprises amino acid sequence respectively. LCDR1-LCDR3 as shown in SEQ ID NOs: 53-55;
  • the immunoglobulin is human IgG
  • each single-chain antibody is respectively connected to the C-terminus of the two heavy chains of immunoglobulin.
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is selected from SEQ ID NO: 57; and the amino acid sequence of the variable region of the light chain of the immunoglobulin is selected from SEQ ID NO: 59;
  • the amino acid sequence of the heavy chain variable region of the chain antibody is selected from SEQ ID NO: 2 and SEQ ID NO: 6; and the amino acid sequence of the light chain variable region of the single chain antibody is selected from SEQ ID NO: 4, SEQ ID NO: 6; NO:8 and SEQ ID NO:64;
  • the amino acid sequence of the heavy chain variable region of the immunoglobulin is selected from SEQ ID NO: 2 and SEQ ID NO: 6; and the amino acid sequence of the light chain variable region of the immunoglobulin is selected from SEQ ID NO: 4 , SEQ ID NO: 8 and SEQ ID NO: 64; and, the amino acid sequence of the heavy chain variable region of the single chain antibody is selected from SEQ ID NO: 57; and the light chain variable region of the single chain antibody
  • the amino acid sequence is selected from SEQ ID NO:59.
  • the method, wherein the bispecific antibody is selected from any one of the following (1)-(6):
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 57, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 59; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 4;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 57, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 59; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 8;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 57, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 59; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO: 64;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 4; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO:57, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO:59;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 8; and, the The amino acid sequence of the variable region of the heavy chain of the single-chain antibody is shown in SEQ ID NO:57, and the amino acid sequence of the variable region of the light chain of the single-chain antibody is shown in SEQ ID NO:59;
  • the amino acid sequence of the variable region of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the variable region of the light chain of the immunoglobulin is shown in SEQ ID NO: 64; and, the The amino acid sequence of the heavy chain variable region of the single chain antibody is shown in SEQ ID NO:57, and the amino acid sequence of the light chain variable region of the single chain antibody is shown in SEQ ID NO:59.
  • the method wherein the heavy chain constant region of the immunoglobulin of the bispecific antibody is selected from the heavy chain constant region of human IgG1, IgG2, IgG3 or IgG4, and the The light chain constant region of the immunoglobulin of the bispecific antibody is selected from the light chain constant region of human IgG1, IgG2, IgG3 or IgG4;
  • the heavy chain constant region of the immunoglobulin of the bispecific antibody is a human Ig gamma-1 chain C region or a human Ig gamma-4 chain C region, and the light chain of the immunoglobulin of the bispecific antibody
  • the constant region is the human Ig kappa chain C region.
  • the immunoglobulin Fc fragment of the bispecific antibody contains the aforementioned mutation, that is, the heavy chain of the immunoglobulin of the bispecific antibody
  • the constant region contains the aforementioned mutations.
  • the method wherein the heavy chain constant region of the immunoglobulin of the bispecific antibody is selected from the heavy chain constant region of human IgG1, IgG2, IgG3 or IgG4, and the The light chain constant region of the immunoglobulin of the bispecific antibody is selected from the light chain constant region of human IgG1, IgG2, IgG3 or IgG4; and the heavy chain constant region of the immunoglobulin of the bispecific antibody according to the EU numbering system Contains the following mutations:
  • the method wherein the heavy chain constant region of the immunoglobulin of the bispecific antibody is a human Ig gamma-1 chain C region or a human Ig gamma-4 chain C region, and
  • the light chain constant region of the immunoglobulin of the bispecific antibody is the human Ig kappa chain C region; and according to the EU numbering system, the heavy chain constant region of the immunoglobulin of the bispecific antibody comprises the following mutations:
  • the method wherein the immune cells are human immune cells, such as human macrophages.
  • the method wherein the method is a method for non-therapeutic purposes.
  • the method wherein the method is a method for pharmaceutical purposes.
  • the method wherein the method is a pharmaceutical method.
  • Another aspect of the present invention relates to a method for improving the efficacy and/or safety of a drug containing an immunoglobulin Fc fragment, wherein, by the method of any one of the present invention, the reduction of immunoglobulin Fc containing Fragments of drug-mediated or induced levels of IL-8 and/or IL-6 secreted by immune cells.
  • the method wherein the method is a pharmaceutical method.
  • variable regions of light and heavy chains determine antigen binding; the variable regions of each chain contain three hypervariable regions, called complementarity determining regions (CDRs) (the CDRs of the heavy chain (H) Comprising HCDR1, HCDR2, HCDR3, the CDRs of the light chain (L) comprise LCDR1, LCDR2, LCDR3; named by Kabat et al, see Sequences of Proteins of Immunological Interest, Fifth Edition (1991), Vols 1-3, NIH Publication 91-3242, Bethesda Md).
  • CDRs complementarity determining regions
  • amino acid sequence of the CDR region of the antibody sequence involved in the present invention is analyzed by technical means well-known to those skilled in the art, for example, through the VBASE2 database, and the results are as follows:
  • amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:2
  • amino acid sequence of the light chain variable region is shown in SEQ ID NO:4.
  • amino acid sequences of the three CDR regions in the variable region of its heavy chain are as follows:
  • HCDR1 GFAFSSYD (SEQ ID NO: 32)
  • HCDR3 ANRYGEAWFAY (SEQ ID NO: 34)
  • amino acid sequences of the three CDR regions of the light chain variable region are as follows:
  • LCDR1 QDINTY (SEQ ID NO: 35)
  • LCDR3 LQYDEFPLT (SEQ ID NO: 37)
  • amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:6, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:8.
  • amino acid sequence of the three CDR regions of the variable region of its heavy chain is the same as that of 14C12.
  • amino acid sequence of the three CDR regions of the light chain variable region is the same as that of 14C12.
  • amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 16;
  • amino acid sequences of the three CDR regions in the variable region of its heavy chain are as follows:
  • HCDR1 GYSFTGYT (SEQ ID NO: 38)
  • HCDR2 INPYNNIT (SEQ ID NO: 39)
  • amino acid sequences of the three CDR regions of the light chain variable region are as follows:
  • LCDR1 TGAVTSNF (SEQ ID NO:41)
  • LCDR2 GTN (SEQ ID NO: 42)
  • LCDR3 ALWYSNHWV (SEQ ID NO: 43)
  • amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:18, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:20;
  • amino acid sequence of the three CDR regions of the variable region of the heavy chain is the same as that of 4G10.
  • amino acid sequence of the three CDR regions of the light chain variable region is the same as that of 4G10.
  • amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:30, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:31;
  • amino acid sequence of the three CDR regions of the variable region of the heavy chain is the same as that of 4G10.
  • amino acid sequence of the three CDR regions of the light chain variable region is the same as that of 4G10.
  • amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:22, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:26;
  • amino acid sequences of the three CDR regions in the variable region of its heavy chain are as follows:
  • HCDR1 GYSFTGYT (SEQ ID NO: 44)
  • HCDR2 INPYNAGT (SEQ ID NO: 45)
  • HCDR3 ARSEYRYGGDYFDY (SEQ ID NO: 46)
  • amino acid sequences of the three CDR regions of the light chain variable region are as follows:
  • LCDR1 QSLLNSSNQKNY (SEQ ID NO: 47)
  • LCDR2 FAS (SEQ ID NO: 48)
  • LCDR3 QQHYDTPYT (SEQ ID NO: 49)
  • amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:57, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:59;
  • amino acid sequences of the three CDR regions in the variable region of its heavy chain are as follows:
  • HCDR1 GGSISDYY (SEQ ID NO: 50)
  • HCDR2 INHRGTT (SEQ ID NO: 51)
  • HCDR3 AFGYSDYEYDWFDP (SEQ ID NO: 52)
  • amino acid sequences of the three CDR regions of the light chain variable region are as follows:
  • LCDR1 QTISSY (SEQ ID NO: 53)
  • LCDR2 DAS (SEQ ID NO: 54)
  • LCDR3 QQRSNWPIT (SEQ ID NO: 55)
  • PD-1 protein Protein 1
  • it includes but is not limited to the full length of PD-1 protein (NCBI GenBank: NP_005009.2), or PD- 1's extracellular fragment PD-1ECD or a fragment comprising PD-1ECD; also includes a fusion protein of PD-1ECD, such as a fragment fused to a mouse or human IgG Fc protein fragment (mFc or hFc).
  • mFc or hFc IgG Fc protein fragment
  • those skilled in the art understand that in the amino acid sequence of PD-1 protein, mutations or variations (including but not limited to substitutions, deletions and/or additions) can be naturally generated or artificially introduced without affecting its biological function.
  • the term "PD-1 protein” shall include all such sequences, as well as natural or artificial variants thereof. And, when describing the sequence fragment of PD-1 protein, it includes not only the sequence fragment, but also the corresponding sequence fragment in its natural or artificial variant.
  • CTLA4 protein when referring to the amino acid sequence of CTLA4 protein, it includes, but is not limited to, the full length of CTLA4 protein (NCBI Genebank ID: NP_054862.1), or the extracellular fragment CTLA4 ECD or a fragment comprising CTLA4 ECD ; also includes fusion proteins of CTLA4 ECD, such as fragments fused to Fc protein fragments (mFc or hFc) of mouse or human IgG.
  • mFc or hFc Fc protein fragments
  • CTLA4 protein shall include all such sequences as well as natural or artificial variants thereof. Also, when describing a sequence fragment of the CTLA4 protein, it includes the CTLA4 sequence fragment, and also includes the corresponding sequence fragment in its natural or artificial variants.
  • CD73 protein when referring to the amino acid sequence of CD73 protein, it includes, but is not limited to, the full length of CD73 protein (NCBI Genebank ID: NP_054862.1), or the extracellular fragment CD73 ECD or CD73 ECD-containing Fragments; also include fusion proteins of CD73 ECD, such as fragments fused to Fc protein fragments (mFc or hFc) of mouse or human IgG.
  • fusion proteins of CD73 ECD such as fragments fused to Fc protein fragments (mFc or hFc) of mouse or human IgG.
  • mutations or variations can be naturally generated or artificially introduced without affecting its biological function.
  • CD73 protein shall include all such sequences as well as natural or artificial variants thereof. Also, when a sequence fragment of the CD73 protein is described, the CD73 sequence fragment is included, as well as the corresponding sequence fragment in its natural or artificial variants.
  • the amino acid sequence of the LAG3 protein when referring to the amino acid sequence of the LAG3 protein, it includes, but is not limited to, the full length of the LAG3 protein (NCBI Genebank ID: NP_002277.4), or the extracellular fragment of LAG3, the LAG3 ECD, or the LAG3 ECD-containing Fragments; also include fusion proteins of LAG3 ECD, such as fragments fused to Fc protein fragments (mFc or hFc) of mouse or human IgG.
  • mFc or hFc Fc protein fragments
  • the term "LAG3 protein” shall include all such sequences as well as natural or artificial variants thereof. Also, when describing a sequence fragment of the LAG3 protein, it includes the LAG3 sequence fragment, and also includes the corresponding sequence fragment in natural or artificial variants thereof.
  • antibody refers to an immunoglobulin molecule generally composed of two pairs of polypeptide chains, each pair having one "light” (L) chain and one "heavy” (H) chain .
  • Antibody light chains can be classified as kappa and lambda light chains.
  • Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
  • the variable and constant regions are linked by a "J" region of about 12 or more amino acids, and the heavy chain also contains a "D" region of about 3 or more amino acids.
  • Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH).
  • the heavy chain constant region consists of 3 domains (CH1, CH2 and CH3).
  • Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL).
  • the light chain constant region consists of one domain, CL.
  • the constant regions of the antibodies mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component (Clq) of the classical complement system.
  • the VH and VL regions can also be subdivided into regions of high variability called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs).
  • CDRs complementarity determining regions
  • Each VH and VL consists of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from amino terminus to carboxy terminus.
  • the variable regions (VH and VL) of each heavy/light chain pair, respectively, form the antibody binding site.
  • the assignment of amino acids to regions or domains follows the Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia (1989) Definition of Nature 342:878-883.
  • the term "antibody” is not limited by any particular method of producing an antibody.
  • Antibodies can be of different isotypes, eg, IgG (eg, IgGl, IgG2, IgG3, or IgG4 subtype), IgAl, IgA2, IgD, IgE, or IgM antibodies.
  • IgG eg, IgGl, IgG2, IgG3, or IgG4 subtype
  • IgAl IgA2, IgD, IgE, or IgM antibodies.
  • the terms "monoclonal antibody” and “monoclonal antibody” refer to an antibody or a fragment of an antibody from a population of highly homologous antibody molecules, that is, excluding natural mutations that may arise spontaneously, A population of identical antibody molecules.
  • Monoclonal antibodies are highly specific for a single epitope on an antigen.
  • Polyclonal antibodies are relative to monoclonal antibodies, which generally comprise at least two or more different antibodies that generally recognize different epitopes on an antigen.
  • Monoclonal antibodies are typically obtained using the hybridoma technology first reported by Kohler et al. (Nature, 256:495, 1975), but can also be obtained using recombinant DNA technology (see, eg, U.S. Patent 4,816,567).
  • humanized antibody refers to the replacement of all or part of the CDR regions of a human immunoglobulin (acceptor antibody) with the CDR regions of a non-human antibody (donor antibody)
  • the antibody or antibody fragment of which the donor antibody can be a non-human (eg, mouse, rat or rabbit) antibody with the desired specificity, affinity or reactivity.
  • some amino acid residues in the framework region (FR) of the acceptor antibody can also be replaced by amino acid residues of corresponding non-human antibodies, or by amino acid residues of other antibodies, to further improve or optimize the performance of the antibody.
  • isolated refers to artificially obtained from the natural state. If an "isolated” substance or component occurs in nature, it may be due to a change in its natural environment, or separation of the substance from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity isolated from this natural state is called isolated of.
  • isolated or isolated
  • the term "vector” refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
  • the vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector.
  • the vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements carried by it can be expressed in the host cell.
  • Vectors are well known to those skilled in the art and include, but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) or P1 derived artificial chromosomes (PACs) ; Phage such as ⁇ phage or M13 phage and animal viruses.
  • YACs yeast artificial chromosomes
  • BACs bacterial artificial chromosomes
  • PACs P1 derived artificial chromosomes
  • Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (eg, herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses Polyoma vacuolar virus (eg SV40).
  • retroviruses including lentiviruses
  • adenoviruses eg, adeno-associated viruses
  • herpesviruses eg, herpes simplex virus
  • poxviruses baculoviruses
  • papillomaviruses papillomaviruses
  • Polyoma vacuolar virus eg SV40
  • a vector may contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and
  • the term "host cell” refers to a cell that can be used to introduce a vector, including, but not limited to, prokaryotic cells such as E. coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, etc., Insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • prokaryotic cells such as E. coli or Bacillus subtilis
  • fungal cells such as yeast cells or Aspergillus, etc.
  • Insect cells such as S2 Drosophila cells or Sf9
  • animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • an antibody that specifically binds to an antigen refers to an antibody that is less than about 10-5 M, such as less than about 10-6 M, 10-7 M, Binds the antigen with an affinity (KD) of 10-8 M, 10-9 M, or 10-10 M or less.
  • KD refers to the dissociation equilibrium constant for a particular antibody-antigen interaction, which is used to describe the binding affinity between an antibody and an antigen.
  • antibodies exhibit a dissociation equilibrium constant (K D ) of less than about 10-5 M, eg, less than about 10-6 M, 10-7 M, 10-8 M, 10-9 M, or 10-10 M or less Binds antigen (eg, PD-1 protein).
  • KD can be determined using methods known to those skilled in the art, eg, using a Fortebio Molecular Interactometer.
  • amino acids are generally represented by one-letter and three-letter abbreviations well known in the art.
  • alanine can be represented by A or Ala.
  • the term "pharmaceutically acceptable carrier and/or excipient” refers to a carrier and/or excipient that is pharmacologically and/or physiologically compatible with the subject and the active ingredient, It is well known in the art (see e.g. Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995) and includes, but is not limited to: pH adjusters, surfactants, adjuvants, ionic strength enhancers agent.
  • pH adjusting agents include but are not limited to phosphate buffers; surfactants include but are not limited to cationic, anionic or nonionic surfactants such as Tween-80; ionic strength enhancers include but are not limited to sodium chloride.
  • the term "effective amount" refers to an amount sufficient to obtain, or at least partially obtain, the desired effect.
  • a disease-prophylactically effective amount refers to an amount sufficient to prevent, arrest, or delay the onset of a disease (eg, a tumor);
  • a therapeutically-effective amount refers to an amount sufficient to cure or at least partially prevent the development of a disease in a patient already suffering from the disease. The amount of disease and its complications. Determination of such effective amounts is well within the purview of those skilled in the art.
  • an amount effective for therapeutic use will depend on the severity of the disease to be treated, the general state of the patient's own immune system, the patient's general condition such as age, weight and sex, the mode of administration of the drug, and other concurrently administered treatments and many more.
  • the term "complete elimination” means no or very low binding signal detected by existing instrumentation (eg, Fortebio Octet Molecular Interactometer).
  • very low binding signal means that the binding signal is below 0.1 nm.
  • fusion protein refers to purposefully linking two or more genes encoding functional proteins together to express the desired protein.
  • immunoglobulin (Ig) fusion protein refers to a recombinant protein with the above two partial domains that is expressed in eukaryotic or prokaryotic cells by linking a target gene with an Ig partial fragment gene at the gene level . According to the connection between the target protein and different fragments of Ig, it can be divided into two categories: one is Fab (Fv) fusion protein; the other is Fc fusion protein.
  • Fc fusion protein refers to a novel protein produced by fusing a certain biologically active functional protein molecule with an Fc fragment using techniques such as genetic engineering. or ligand) soluble ligand (or receptor) molecules or other active substances (such as cytokines) that need to prolong the half-life.
  • Fc fusion proteins mainly combine biologically active proteins with the hinge region and the CH2 and CH3 regions of Ig.
  • Fc fragment or “Fc fragment”, also known as fragment crystallizable.
  • cytokine is a small molecular weight regulatory protein secreted by a cell that affects cell behavior (activation, proliferation, differentiation, migration, etc.).
  • chemokines is a special class of cytokines, low molecular weight proteins that affect leukocyte chemotaxis and other cellular behaviors, and play an important role in the middle stage of inflammatory response.
  • the letters before the site represent the amino acid before mutation
  • the letters after the site represent the amino acid after mutation
  • the present invention achieves one or more of the technical effects described in the following items (1) to (2):
  • the present invention can effectively inhibit, reduce or eliminate the secretion of IL-6 and/or IL-8 of immune cells mediated or induced by antibody drugs;
  • the present invention can also effectively eliminate the unexpected secretion of IL-6 and/or IL-8 in medicines containing Fc fragments, such as Fc fusion protein medicines.
  • Figure 1 In the co-culture system of CHO-K1-PD1-CTLA4 cells and human macrophages, amino acid mutations in the Fc segment effectively abolished the secretion of IL-8 from human macrophages mediated by anti-PD-1/CTLA4 bispecific antibody .
  • Figure 2 In the co-culture system of CHO-K1-PD1-CTLA4 cells and human macrophages, amino acid mutations in the Fc segment effectively abolished the secretion of IL-6 from human macrophages mediated by anti-PD-1/CTLA4 bispecific antibody .
  • Figure 3 In the co-culture system of CHO-K1-PD1 cells and human macrophages, amino acid mutations in the Fc segment effectively abolished the secretion of IL-8 from human macrophages mediated by anti-PD-1/CD73 bispecific antibody.
  • Figure 4 In the co-culture system of CHO-K1-PD1 cells and human macrophages, amino acid mutations in the Fc segment effectively abolished the secretion of IL-6 from human macrophages mediated by anti-PD-1/CD73 bispecific antibody.
  • Figure 5 In the co-culture system of U87-MG cells and human macrophages, amino acid mutations in the Fc segment effectively abolished the secretion of IL-8 from human macrophages mediated by anti-PD-1/CD73 bispecific antibody.
  • Figure 6 In the co-culture system of U87-MG cells and human macrophages, the amino acid mutation of the Fc segment effectively eliminated the secretion of IL-6 by human macrophages mediated by anti-PD-1/CD73 bispecific antibody.
  • Figure 7 In the co-culture system of CHO-K1-PD1-LAG3 cells and human macrophages, the amino acid mutation in the Fc segment effectively eliminated the secretion of IL-8 from human macrophages mediated by anti-PD-1/LAG3 bispecific antibody .
  • Figure 8 In the co-culture system of CHO-K1-PD1-LAG3 cells and human macrophages, the amino acid mutation in the Fc segment effectively eliminated the secretion of IL-6 by human macrophages mediated by anti-PD-1/LAG3 bispecific antibody .
  • mice used were purchased from the Guangdong Provincial Medical Laboratory Animal Center.
  • the IgG4 subtype anti-PD-1 antibody Nivolumab (trade name Opdivo) carrying the S228P mutation (Wang C et al. Cancer Immunol Res. 2014; 2(9): 846-56.) was used, and the Fc end was retained.
  • the IgG1 subtype Ipilimumab (trade name Yervoy) with Fc ⁇ R function was purchased from Bristol-Myers Squibb as the control antibody; the IgG4 subtype Relatlimab was used as the control antibody, which was made by Zhongshan Kangfang Biopharmaceutical Co., Ltd., batch number: 20200630.
  • the heavy chain variable region and light chain variable region sequences of the anti-CD73 antibody 19F3H2L3 (hG1WT) used are the same as those of 19F3H2L3 (hG1TM) in Preparation Example 2, and the constant region fragment adopts Ig gamma -1 chain C region, ACCESSION:P01857 is the heavy chain constant region, Ig kappa chain C region, ACCESSION:P01834 is the light chain constant region.
  • the used isotype control antibodies namely hIgG1 and hIgG4, are antibodies targeting human anti-egg lysosome (HEL), and the variable region sequences of these antibodies are from the published by Acierno et al. Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies (Acierno et al. J Mol Biol.
  • the constant region fragment of hIgG1 adopts Ig gamma-1 chain C region, ACCESSION: P01857 as the heavy chain constant region, Ig kappa chain C region, ACCESSION: P01834 as the light chain constant region; hIgG4 heavy chain constant region adopts the Ig gamma-4 chain C region, ACCESSION: P01861.1 as the heavy chain constant region And introduce S228P mutation to improve stability, Ig kappa chain C region, ACCESSION: P01834 is the light chain constant region; hIgG1, hIgG1 (DM) and hIgG4 are all made in the laboratory of Zhongshan Kangfang Biopharmaceutical Co., Ltd.
  • the structural pattern of the bispecific antibody BiAb004 belongs to the Morrison pattern (IgG-scFv), that is, at the C-terminus of both heavy chains of an immunoglobulin part (IgG) antibody, the scFv fragments of the other antibody are connected by linker fragments.
  • its immunoglobulin part is based on PD-1 antibody
  • the scFv fragment is based on anti-CTLA4 antibody
  • the middle is linked by a linker fragment.
  • Anti-PD-1 antibody 14C12 and its humanized antibody 14C12H1L1 have heavy chain and light chain variable region amino acid sequences and coding nucleic acid sequences that are identical to 14C12 and 14C12H1L1 in Chinese Patent Publication CN 106967172A, respectively.
  • amino acid sequences of the heavy chain and light chain of the anti-CTLA4 antibody 4G10 and its humanized antibody 4G10H3L3, and the coding nucleic acid sequences are respectively identical to 4G10 and 4G10H3L3 in Chinese Patent Publication CN 106967172A.
  • the structural pattern of the bispecific antibody BiAb004(M) belongs to the Morrison pattern (IgG-scFv), that is, the C-terminus of the two heavy chains of one IgG antibody is connected to the scFv fragment of the other antibody through a linker fragment.
  • the design composition of the chain is shown in Table 1 below.
  • the amino acid sequence of Linker is GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:29)
  • 4G10H3V (M) and 4G10L3V (M) in the scFv fragment of BiAb004 (M) antibody in the above table 1 are based on 4G10H3V and 4G10L3V. Individual amino acids in the framework region were mutated, which effectively optimized the antibody structure, increasing its effectiveness.
  • BiAb004(M) is regarded as "wild type", also referred to as BiAb004(hG1WT) in the examples of the present invention.
  • BiAb004 (hG1WT) adopts the Ig gamma-1 chain C region, ACCESSION:P01857 as the heavy chain constant region of the immunoglobulin part, and the Ig kappa chain C region, ACCESSION:P01834 as the light chain constant region of the immunoglobulin part.
  • Non-variable region amino acid mutation design based on humanized bispecific antibody BiAb004 (hG1WT)
  • BiAb004 (hG1WT) obtained above, the present inventors introduced a point mutation (L234A) from leucine to alanine at the 234th position of its heavy chain according to the EU numbering system, the 235th A leucine-to-alanine point mutation (L235A) was introduced at the No. 237 position, and a glycine-to-alanine point mutation (G237A) was introduced at the No. 237 position to obtain BiAb004 (hG1TM). The rest of the amino acid sequence is exactly the same as BiAb004 (hG1WT).
  • the structural pattern of the bispecific antibody NTPDV2 belongs to the Morrison pattern (IgG-scFv), that is, the C-terminus of the two heavy chains of one IgG antibody is connected to the scFv fragment of the other antibody through a linker fragment.
  • the design composition of the chain is shown in Table 2 below.
  • NTPDV2 (hG1TM) uses the Ig gamma-1 chain C region, ACCESSION:P01857 as the heavy chain constant region of the immunoglobulin part, and uses the Ig kappa chain C region, ACCESSION:P01834 as the light chain constant region of the immunoglobulin part, and On this basis, three mutations were made according to the EU numbering system: L234A, L235A and G237A.
  • amino acid sequence of 14C12H1V is shown in SEQ ID NO:6 preceding it.
  • amino acid sequence of 14C12L1V is shown in SEQ ID NO: 8 preceding it.
  • the nucleic acid sequence encoding the heavy chain variable region of 19F3H2 (hG1TM) is as follows (363 bp), and the CDR coding region is underlined:
  • the amino acid sequence of the heavy chain variable region of 19F3H2 (hG1TM) is as follows (121aa), the CDR regions are underlined:
  • the nucleic acid sequence encoding the heavy chain of 19F3H2 (hG1TM) is as follows (1353bp):
  • amino acid sequence of the heavy chain of 19F3H2 (hG1TM) is as follows (451aa), the CDR regions are underlined:
  • nucleic acid sequence (339 bp) encoding the light chain variable region of 19F3L3 is as follows:
  • amino acid sequence (113aa) of the light chain variable region of 19F3L3 is as follows:
  • 19F3L3 is used as the light chain of the immunoglobulin part of NTPDV2 (hG1TM), and the nucleic acid sequence (660bp) encoding 19F3L3 is as follows:
  • 19F3L3 is used as the light chain of the immunoglobulin part of NTPDV2 (hG1TM), and its amino acid sequence is as follows (220aa), wherein the CDR region is underlined and shown in bold:
  • the structural pattern of the bispecific antibody Bs-PL022B belongs to the Morrison pattern (IgG-scFv), that is, at the C-terminus of the two heavy chains of one IgG antibody, the scFv fragments of the other antibody are connected by linking fragments, and its heavy chain and the design composition of the light chain is shown in Table 3 below.
  • Bs-PL022B (hG1TM) uses the Ig gamma-1 chain C region, ACCESSION:P01857 as the heavy chain constant region of the immunoglobulin part, and uses the Ig kappa chain C region, ACCESSION:P01834 as the light chain constant region of the immunoglobulin part , and on this basis, three mutations were made according to the EU numbering system: L234A, L235A, L237A.
  • Fc segment mutation can effectively eliminate the anti-PD-1/CTLA4 bispecific anti-PD-1/CTLA4 immune checkpoint inhibitor.
  • HPMM Human peripheral monocyte derived macrophage
  • PBMC peripheral blood mononuclear cells
  • Ficoll-Paque TM PLUS Lymphocyte Separation Solution (GE, Cat. No.: 17-1440-03); RPMI 1640 (Gibco, Cat. No.: 22400-105); CHO-K1-PD1-CTLA4 cells (constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. ); FBS (Fetal Bovine Serum, Excell bio, Cat. No.: FSP500); Human IFN- ⁇ protein (sinobio, Cat. No.: 11725-HNAS-100); LPS (Lipopolysaccharides), lipopolysaccharide (sigma, Cat. No.: L4391); 96-well Cell culture plates (Corning, Cat. No. 3599).
  • PBMC peripheral blood mononuclear cells
  • CHO-K1 cells expressing human PD-1 and CTLA4, namely CHO-K1-PD1-CTLA4 cells adjust the number of cells to 30,000/100 ⁇ L/well; dilute the antibody with complete 1640 medium (working concentration: 25nM, 2.5 nM, 0.25nM), add 100 ⁇ L of antibody dilution to each well according to the experimental design, mix well, and design isotype control wells.
  • Lipopolysaccharide was used as a positive control drug, and the concentration was adjusted to 100 ng/mL from the complete medium in the experiment.
  • the cell plates were placed in an incubator for 24 h. After centrifugation at 1200 rpm for 5 min, the supernatant was collected and the secretion of IL-8 and IL-6 was detected by Daktronics kit.
  • co-culture of CHO-K1-PD1-CTLA4 cells as target cells with HPMM can induce HPMM activation.
  • the activated HPMM is linked to the target cells through the antibody Fab, the Fc fragment of the antibody interacts with the Fc ⁇ R on HPMM, causing HPMM to secrete cells factor.
  • HPMM is induced by PBMC.
  • the PBMCs used in this study were all isolated and prepared in Zhongshan Kangfang Biopharmaceutical Co., Ltd., and informed consent was obtained from the providers.
  • Ficoll-Paque TM PLUS Lymphocyte Separation Solution (GE, Item No.: 17-1440-03); RPMI 1640 (Gibco, Item No.: 22400-105); CHO-K1-PD1 cells (constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd.); U87-MG cells (cells from ATCC, purchased from Beijing Zhongyuan Leading Technology Co., Ltd.); FBS (Fetal Bovine Serum, Excell bio, product number: FSP500); human IFN- ⁇ protein (sinobio, product number: 11725-HNAS-100) ; LPS (Lipopolysaccharides), lipopolysaccharide (sigma, Cat. No.: L4391); 96-well cell culture plate (Corning, Cat. No. 3599).
  • GE Ficoll-Paque TM PLUS Lymphocyte Separation Solution
  • RPMI 1640 Gibco, Item No.: 22400-105
  • Healthy human PBMCs were isolated according to the instructions of the Ficoll-Paque TM Plus reagent for separation medium and resuspended in 1640 medium containing 2% FBS and placed in a 37°C, 5% CO 2 cell incubator. After 2 h, the supernatant was removed, the adherent cells were washed twice with PBS, and induced for 7 days by adding 1640 complete medium (containing 10% FBS) and 100 ng/mL human M-CSF. The medium was changed on days 3 and 5 and supplemented with M-CSF to induce HPMM. On the 7th day, HPMM was collected after induction, and the concentration was adjusted to 100,000/mL with complete medium and dispensed into 96-well plates.
  • Recombinant human IFN- ⁇ (50ng/mL) was added, and the cells were incubated in an incubator for 24h. 24h later, the log-phase CHO-K1-PD1 cells expressing human PD-1 or U87-MG cells constitutively expressing human CD73 were collected, and the concentration was adjusted to 300,000/mL with complete medium after resuspending. Antibodies were diluted in complete medium to working concentrations of 25nM, 2.5nM, 0.25nM. At the same time, an isotype control antibody and a blank control were designed.
  • co-culture of CHO-K1-PD1 and U87-MG cells as target cells with HPMM can induce HPMM activation.
  • the activated HPMM is linked to the target cells through the antibody Fab, the antibody Fc segment interacts with the Fc ⁇ R on HPMM, causing HPMM secretes cytokines.
  • the anti-PD-1/CD73 bispecific antibody carrying the Fc segment mutation can effectively eliminate the IL-6 and/or IL of immune cells. -8 secretion.
  • the anti-PD-1/CD73 bispecific antibody with Fc mutation can also effectively eliminate IL-6 and IL-6 from immune cells. /or secretion of IL-8.
  • HPMM Human peripheral monocyte derived macrophage
  • PBMC peripheral blood mononuclear cells
  • Ficoll-Paque TM PLUS Lymphocyte Separation Solution (GE, Cat. No.: 17-1440-02); RPMI 1640 (Gibco, Cat. No.: 22400-105); CHO-K1-PD1-LAG3 cells (constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. ); FBS (Fetal Bovine Serum, Excell bio, Cat. No.: FSP500); Human IFN- ⁇ protein (sinobio, Cat. No.: 11725-HNAS-100); LPS (Lipopolysaccharides, sigma, Cat. No.: L6529); 96-well cell culture plate ( Corning, Cat. No. 3599).
  • PBMC peripheral blood mononuclear cells
  • CHO-K1 cells expressing human PD-1 and LAG3, namely CHO-K1-PD1-LAG3 cells adjust the number of cells to 30,000/100 ⁇ L/well; dilute the antibody with 1640 complete medium (working concentration: 25nM, 2.5 nM, 0.25nM), add 100 ⁇ L of antibody dilution to each well according to the experimental design, mix well, and design isotype control wells.
  • Lipopolysaccharide was used as a positive control drug, and the concentration was adjusted to 100 ng/mL from the complete medium in the experiment.
  • the cell plates were placed in an incubator for 24 h. The cell plate was taken out and centrifuged at 1200 rpm for 5 min, the supernatant was collected, and the secretion of IL-8 and IL-6 was detected by Daktronics kit.
  • co-culture of CHO-K1-PD1-LAG3 cells as target cells with HPMM can induce HPMM activation.
  • the activated HPMM is linked to the target cells through the antibody Fab, the antibody Fc fragment interacts with the Fc ⁇ R on HPMM, causing HPMM to secrete cells factor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé d'optimisation d'un médicament contenant un fragment Fc d'immunoglobuline pour améliorer l'innocuité et/ou l'efficacité du médicament. De façon spécifique, l'invention concerne un procédé de réduction ou de blocage du niveau d'IL-8 et/ou d'IL-6 secrétés par une cellule immunitaire médiée par un médicament contenant un fragment Fc d'immunoglobuline. Le procédé peut améliorer efficacement l'innocuité et/ou l'efficacité du médicament contenant le fragment Fc d'immunoglobuline.
PCT/CN2022/080392 2021-03-12 2022-03-11 Procédé d'amélioration de l'innocuité d'un médicament contenant un fragment fc d'immunoglobuline WO2022188867A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110270671.X 2021-03-12
CN202110270671 2021-03-12

Publications (1)

Publication Number Publication Date
WO2022188867A1 true WO2022188867A1 (fr) 2022-09-15

Family

ID=83226290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/080392 WO2022188867A1 (fr) 2021-03-12 2022-03-11 Procédé d'amélioration de l'innocuité d'un médicament contenant un fragment fc d'immunoglobuline

Country Status (2)

Country Link
CN (1) CN115073588A (fr)
WO (1) WO2022188867A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023051621A1 (fr) * 2021-09-29 2023-04-06 中山康方生物医药有限公司 Anticorps anti-lag3, composition pharmaceutique et utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105793287A (zh) * 2013-09-20 2016-07-20 百时美施贵宝公司 抗lag-3抗体与抗pd-1抗体联合治疗肿瘤
CN106967172A (zh) * 2016-08-23 2017-07-21 中山康方生物医药有限公司 抗ctla4‑抗pd‑1 双功能抗体、其药物组合物及其用途
CN112300280A (zh) * 2019-08-02 2021-02-02 正大天晴康方(上海)生物医药科技有限公司 一种抗pd-1抗体及其医药用途
CN112300286A (zh) * 2019-08-02 2021-02-02 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体及其用途
WO2021213475A1 (fr) * 2020-04-22 2021-10-28 中山康方生物医药有限公司 Anticorps bispécifique anti-cd73-anti-pd-1 et son utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105793287A (zh) * 2013-09-20 2016-07-20 百时美施贵宝公司 抗lag-3抗体与抗pd-1抗体联合治疗肿瘤
CN106967172A (zh) * 2016-08-23 2017-07-21 中山康方生物医药有限公司 抗ctla4‑抗pd‑1 双功能抗体、其药物组合物及其用途
CN112300280A (zh) * 2019-08-02 2021-02-02 正大天晴康方(上海)生物医药科技有限公司 一种抗pd-1抗体及其医药用途
CN112300286A (zh) * 2019-08-02 2021-02-02 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体及其用途
WO2021023117A1 (fr) * 2019-08-02 2021-02-11 康方药业有限公司 Anticorps anti-ctla4-anti-pd-1 bispécifique et ses utilisations
WO2021213475A1 (fr) * 2020-04-22 2021-10-28 中山康方生物医药有限公司 Anticorps bispécifique anti-cd73-anti-pd-1 et son utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FINCO D., GRIMALDI C., FORT M., WALKER M., KIESSLING A., WOLF B., SALCEDO T., FAGGIONI R., SCHNEIDER A., IBRAGHIMOV A., SCESNEY S.: "Cytokine release assays: Current practices and future directions", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 66, no. 2, 1 April 2014 (2014-04-01), US , pages 143 - 155, XP055964902, ISSN: 1043-4666, DOI: 10.1016/j.cyto.2013.12.009 *
LI B., Z. HUANG, X. PANG, T. ZHONG, C. JIN, N. CHEN, S. MA, X. HE, D. XIA, X. JIN, Z. WANG, Y. XIA: "Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties", ANNALS OF ONCOLOGY, vol. 32, no. 5, 1 September 2021 (2021-09-01), XP055964899, DOI: 10.1016/j.annonc.2021.08.280 *
LISA T. C. VOGELPOEL, BAETEN DOMINIQUE L. P., DE JONG ESTHER C., DEN DUNNEN JEROEN: "Control of cytokine production by human Fc gamma receptors: implications for pathogen defense and autoimmunity", FRONTIERS IN IMMUNOLOGY, vol. 6, pages 1 - 11, XP055312134, DOI: 10.3389/fimmu.2015.00079 *
XINHUA WANG, MARY MATHIEU, RANDALL J. BREZSKI: "IgG Fc engineering to modulate antibody effector functions", PROTEIN & CELL, SPRINGER ASIA, BEIJING, CN, vol. 9, no. 1, 1 January 2018 (2018-01-01), Beijing, CN , pages 63 - 73, XP055457296, ISSN: 1674-800X, DOI: 10.1007/s13238-017-0473-8 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023051621A1 (fr) * 2021-09-29 2023-04-06 中山康方生物医药有限公司 Anticorps anti-lag3, composition pharmaceutique et utilisation

Also Published As

Publication number Publication date
CN115073588A (zh) 2022-09-20

Similar Documents

Publication Publication Date Title
JP7308560B2 (ja) 相同二量体型二重特異性抗体およびその調製方法と使用
WO2017071625A1 (fr) Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci
WO2019149269A1 (fr) Fragment variable à chaîne unique anti-antigène de maturation des lymphocytes b (bcma) entièrement humain, et application associée
JP7106234B2 (ja) 二重特異性抗体を製造する方法、二重特異性抗体及びこのような抗体の治療的使用
WO2017148424A1 (fr) Anticorps anti-pdl-1, composition pharmaceutique et utilisations de celui-ci
TWI736437B (zh) 細胞傷害誘導治療劑
WO2018036472A1 (fr) Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci
CN112142847B (zh) 改造的Fc片段，包含其的抗体及其应用
US20220002412A1 (en) Humanized Anti-PD-1 Antibody and The Use Thereof
WO2021213475A1 (fr) Anticorps bispécifique anti-cd73-anti-pd-1 et son utilisation
JP7093794B2 (ja) 免疫関連障害のための抗体－サイトカイングラフト化タンパク質及び使用方法
TWI803718B (zh) 與gitr特異性結合的單株抗體
CN114555639A (zh) 特异性识别白细胞介素-4受体α的抗体及其用途
WO2019242619A1 (fr) Anticorps anti-lag-3 complètement humanisé et son application
US20220324975A1 (en) Antibody cleavage site binding molecule
WO2022188867A1 (fr) Procédé d'amélioration de l'innocuité d'un médicament contenant un fragment fc d'immunoglobuline
WO2022083723A1 (fr) Anticorps anti-cd73 et son utilisation
US20230322898A1 (en) Pharmaceutical composition comprising cell expressing chimeric receptor
AU2022261268A1 (en) Bispecific multifunctional fusion polypeptide
TW202321304A (zh) 抗ｃｃｒ８抗體
KR20230024421A (ko) C5a를 특이적으로 인식하는 항체 및 그의 응용
KR20220143869A (ko) 항-il-2 항체, 이의 항원-결합 단편 및 이의 의학적 용도
WO2023160647A1 (fr) Composition pharmaceutique comprenant un anticorps bispécifique anti-ctla4-anti-pd-1 et du chiauranib
WO2023020625A1 (fr) PROTÉINE DE FUSION CONTENANT UN ANTICORPS ANTI-TIGIT ET UN TGF-βR, ET COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉE
CN117624372A (zh) 靶向cd40和pd-l1的抗体及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22766389

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22766389

Country of ref document: EP

Kind code of ref document: A1